Kestra Medical Technologies (NASDAQ:KMTS) Downgraded by Wall Street Zen to “Sell”

Kestra Medical Technologies (NASDAQ:KMTS) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also recently issued reports on the stock. BTIG Research increased their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Finally, The Goldman Sachs Group cut their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $27.83.

Kestra Medical Technologies Price Performance

Shares of KMTS stock opened at $24.42 on Friday. Kestra Medical Technologies has a twelve month low of $14.10 and a twelve month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 7.32 and a debt-to-equity ratio of 0.16. The stock has a fifty day simple moving average of $22.28 and a two-hundred day simple moving average of $22.72. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -10.09 and a beta of 0.47.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The firm had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. On average, analysts predict that Kestra Medical Technologies will post -2.3 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the completion of the sale, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 3.60% of the stock is owned by insiders.

Institutional Trading of Kestra Medical Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its holdings in shares of Kestra Medical Technologies by 137.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after acquiring an additional 2,529,851 shares in the last quarter. Brown Advisory Inc. increased its stake in Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Kestra Medical Technologies by 13.7% in the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after buying an additional 179,885 shares during the last quarter. Eventide Asset Management LLC lifted its stake in shares of Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares during the period. Finally, Franklin Resources Inc. lifted its position in Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after acquiring an additional 612,343 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.